Research Progress on 18F-Labeled Agents for Imaging of Myocardial Perfusion with Positron Emission Tomography

Tiantian Mou; Xianzhong Zhang

doi:10.3390/molecules22040562

Research Progress on ¹⁸F-Labeled Agents for Imaging of Myocardial Perfusion with Positron Emission Tomography

Molecules. 2017 Mar 30;22(4):562. doi: 10.3390/molecules22040562.

Authors

Tiantian Mou¹, Xianzhong Zhang²

Affiliations

¹ Department of Nuclear Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China. mtt207@163.com.
² State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, China. zhangxzh@xmu.edu.cn.

Abstract

Coronary artery disease (CAD) is the leading cause of death in the world. Myocardial perfusion imaging (MPI) plays a significant role in non-invasive diagnosis and prognosis of CAD. However, neither single-photon emission computed tomography nor positron emission tomography clinical MPI agents can absolutely satisfy the demands of clinical practice. In the past decades, tremendous developments happened in the field of ¹⁸F-labeled MPI tracers. This review summarizes the current state of ¹⁸F-labeled MPI tracers, basic research data of those tracers, and the future direction of MPI tracer research.

Keywords: 18F-labeled radiotracers; lipophilic cations; mitochondrial complex-1; myocardial perfusion imaging; positron emission tomography.

Publication types

Review

MeSH terms

Clinical Trials as Topic
Coronary Artery Disease / diagnostic imaging*
Coronary Artery Disease / metabolism
Fluorine Radioisotopes / metabolism*
Humans
Myocardial Perfusion Imaging / methods*
Positron-Emission Tomography / methods*
Radioactive Tracers
Radiopharmaceuticals / metabolism*

Substances

Fluorine Radioisotopes
Radioactive Tracers
Radiopharmaceuticals